25 July 2023
25 July 2023
Shares in the company dropped by 29% despite assurances the failure would not harm its 2023 financial outlook.
The EMA’s decision marks a further step in the biosimilar’s pathway to potential approval and launch amid an ongoing legal battle.
The positive opinion is based on findings from two global Phase IIb/III clinical trials of cabotegravir LA for PrEP.
The IT company will aid Gilead in quickly bringing its medicines for serious ailments to the market.
The oral P2X7 receptor antagonists offer a new treatment approach for both early-stage DR and dry AMD.
ImmunoBiochem will secure an upfront payment in return for granting ImmunoGen an exclusive license to its current antibodies.
The award comes after opaganib was granted a product pipeline development contract under the US government’s RNCP.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
